Equianalgesic dose guidelines for long-term opioid use: Theoretical and practical considerations

Seminars in Anesthesia, Perioperative Medicine and Pain

Volumn 23, Issue 4, 2004, Pages 271-280

  Souter, Karen J ^a   Fitzgibbon, Dermot ^a  

^a UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; BUTORPHANOL; FENTANYL; HYDROMORPHONE; METHADONE; MORPHINE; MORPHINE 3 GLUCURONIDE; MORPHINE 6 GLUCURONIDE; NALBUPHINE; OPIATE; OXYCODONE; PETHIDINE;

COGNITIVE DEFECT; DELIRIUM; DRUG TOLERANCE; HALLUCINATION; HUMAN; LONG TERM CARE; MYOCLONUS; NAUSEA; PATIENT CONTROLLED ANALGESIA; PRIORITY JOURNAL; REVIEW;

EID: 12844255019     PISSN: 02770326     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.sane.2004.06.001     Document Type: Article

References (82)

1. Agency for Health Care Policy and Research. Management of cancer pain adults. Am J Hosp Pharm. 51:1994;1643-1656
2. Chou R., Clark E., Helfand M. Comparative efficacy and safety of long-acting oral opioids for chronic non-cancer pain A systematic review. J Pain Symptom Manage. 26:2003;1026-1048
3. Cherny N.I. Opioid analgesics Comparative features and prescribing guidelines. Drugs. 51:1996;713-737
4. Foley K.M. The treatment of cancer pain. N Engl J Med. 313:1985;84-95
5. Moulin D.E., Iezzi A., Amireh R., et al. Randomised trial of oral morphine for chronic non-cancer pain. Lancet. 347:1996;143-147
6. Watson C.P., Babul N. Efficacy of oxycodone in neuropathic pain A randomized trial in postherpetic neuralgia. Neurology. 50:1998;1837-1841
7. Caldwell J.R., Hale M.E., Boyd R.E., et al. Treatment of osteoarthritis pain with controlled release oxycodone or fixed combination oxycodone plus acetaminophen added to nonsteroidal antiinflammatory drugs A double blind, randomized, multicenter, placebo controlled trial. J Rheumatol. 26:1999;862-869
8. Roth S.H., Fleischmann R.M., Burch F.X., et al. Around-the-clock, controlled-release oxycodone therapy for osteoarthritis-related pain Placebo-controlled trial and long-term evaluation. Arch Intern Med. 160:2000;853-860
9. Maier C., Hildebrandt J., Klinger R., et al. Morphine responsiveness, efficacy and tolerability in patients with chronic non-tumor associated pain Results of a double-blind placebo-controlled trial (MONTAS). Pain. 97:2002;223-233
10. Groth C.T., Eriksen J., Borgbjerg F.M. Legal opioid consumption in Denmark 1981-1993. Eur J Clin Pharmacol. 48:1995;321-325
11. Thomsen A.B., Becker N., Eriksen J. Opioid rotation in chronic non-malignant pain patients. A retrospective study. Acta Anaesthesiol Scand. 43:1999;918-923
12. Portenoy R.K., Foley K.M. Chronic use of opioid analgesics in non-malignant pain Report of 38 cases. Pain. 25:1986;171-186
13. Cleeland C.S., Gonin R., Hatfield A.K., et al. Pain and its treatment in outpatients with metastatic cancer. N Engl J Med. 330:1994;592-596
14. World Health Organization (WHO). Cancer Pain Relief. 1986;WHO, Geneva
15. Zech D.F., Grond S., Lynch J., et al. Validation of World Health Organization Guidelines for cancer pain relief A 10-year prospective study. Pain. 63:1995;65-76
16. Gammaitoni A.R., Fine P., Alvarez N., et al. Clinical application of opioid equianalgesic data. Clin J Pain. 19:2003;286-297
17. Flores C.M., Mogil J.S. The pharmacogenetics of analgesia Toward a genetically-based approach to pain management. Pharmacogenomics. 2:2001;177-194
18. Kest B., Sarton E., Dahan A. Gender differences in opioid-mediated analgesia Animal and human studies. Anesthesiology. 93:2000;539-547
19. Chia Y.Y., Liu K., Wang J.J., et al. Intraoperative high dose fentanyl induces postoperative fentanyl tolerance. Can J Anaesth. 46:1999;872-877
20. Guignard B., Bossard A.E., Coste C., et al. Acute opioid tolerance Intraoperative remifentanil increases postoperative pain and morphine requirement. Anesthesiology. 93:2000;409-417
21. Cortinez L.I., Brandes V., Munoz H.R., et al. No clinical evidence of acute opioid tolerance after remifentanil-based anaesthesia. Br J Anaesth. 87:2001;866-869
22. Gustorff B., Nahlik G., Hoerauf K.H., et al. The absence of acute tolerance during remifentanil infusion in volunteers. Anesth Analg. 94:2002;1223-1238
23. Anderson R., Saiers J.H., Abram S., et al. Accuracy in equianalgesic dosing conversion dilemmas. J Pain Symptom Manage. 21:2001;397-406
24. Mercadante S. Opioid rotation for cancer pain Rationale and clinical aspects. Cancer. 86:1999;1856-1866
25. Pereira J., Lawlor P., Vigano A., et al. Equianalgesic dose ratios for opioids. A critical review and proposals for long-term dosing. J Pain Symptom Manage. 22:2001;672-687
26. Lawlor P., Pereira J., Bruera E. Dose ratios among different opioids update on the use of the equianalgesic table. Bruera E., Portenoy R. Topics in Palliative Care. 2001;247-276 Oxford University Press, New York
27. de Stoutz N.D., Bruera E., Suarez-Almazor M. Opioid rotation for toxicity reduction in terminal cancer patients. J Pain Symptom Manage. 10:1995;378-384
28. Bruera E., Franco J.J., Maltoni M., et al. Changing pattern of agitated impaired mental status in patients with advanced cancer Association with cognitive monitoring, hydration, and opioid rotation. J Pain Symptom Manage. 10:1995;287-291
29. Ashby M.A., Martin P., Jackson K.A. Opioid substitution to reduce adverse effects in cancer pain management. Med J Aust. 170:1999;68-71
30. Peterson G.M., Randall C.T., Paterson J. Plasma levels of morphine and morphine glucuronides in the treatment of cancer pain Relationship to renal function and route of administration. Eur J Clin Pharmacol. 38:1990;121-124
31. MacDonald N., Der L., Allan S., et al. Opioid hyperexcitability The application of alternate opioid therapy. Pain. 53:1993;353-355
32. Galer B.S., Coyle N., Pasternak G.W., et al. Individual variability in the response to different opioids Report of five cases. Pain. 49:1992;87-91
33. Pick C.G., Cheng J., Paul D., et al. Genetic influences in opioid analgesic sensitivity in mice. Brain Res. 566:1991;295-298
34. Kanner R.M., Foley K.M. Patterns of narcotic drug use in a cancer pain clinic. Ann NY Acad Sci. 362:1981;161-172
35. Liu J.G., Anand K.J. Protein kinases modulate the cellular adaptations associated with opioid tolerance and dependence. Brain Res Brain Res Rev. 38:2001;1-19
36. Moulin D.E., Ling G.S., Pasternak G.W. Unidirectional analgesic cross-tolerance between morphine and levorphanol in the rat. Pain. 33:1988;233-239
37. Russell R.D., Chang K.J. Alternated delta and mu receptor activation A stratagem for limiting opioid tolerance. Pain. 36:1989;381-389
38. Rossi G.C., Brown G.P., Leventhal L., et al. Novel receptor mechanisms for heroin and morphine-6 beta-glucuronide analgesia. Neurosci Lett. 216:1996;1-4
39. Sosnowski M., Yaksh T.L. Differential cross-tolerance between intrathecal morphine and sufentanil in the rat. Anesthesiology. 73:1990;1141-1147
40. Paronis C.A., Holtzman S.G. Development of tolerance to the analgesic activity of mu agonists after continuous infusion of morphine, meperidine or fentanyl in rats. J Pharmacol Exp Ther. 262:1992;1-9
41. Duttaroy A., Yoburn B.C. The effect of intrinsic efficacy on opioid tolerance. Anesthesiology. 82:1995;1226-1236
42. Levy M.H. Pharmacologic treatment of cancer pain. N Engl J Med. 335:1996;1124-1132
43. Houde R., Wallenstein S., Beaver W. Clinical measurement of pain. de Stevens G. Analgetics. 1965;75-122 Academic Press, New York, NY
44. Stanski D.R., Greenblatt D.J., Lowenstein E. Kinetics of intravenous and intramuscular morphine. Clin Pharmacol Ther. 24:1978;52-59
45. Stuart-Harris R., Joel S.P., McDonald P., et al. The pharmacokinetics of morphine and morphine glucuronide metabolites after subcutaneous bolus injection and subcutaneous infusion of morphine. Br J Clin Pharmacol. 49:2000;207-214
46. Nelson K.A., Glare P.A., Walsh D., et al. A prospective, within-patient, crossover study of continuous intravenous and subcutaneous morphine for chronic cancer pain. J Pain Symptom Manage. 13:1997;262-267
47. Moulin D.E., Kreeft J.H., Murray-Parsons N., et al. Comparison of continuous subcutaneous and intravenous hydromorphone infusions for management of cancer pain. Lancet. 337:1991;465-468
48. Expert working group of the European Association for Palliative Care. Fortnightly Review: Morphine in cancer pain: Modes of administration. BMJ. 312:1996;823-826
49. Bruera E., Pereira J., Watanabe S., et al. Opioid rotation in patients with cancer pain. A retrospective comparison of dose ratios between methadone, hydromorphone, and morphine. Cancer. 78:1996;852-857
50. Lawlor P., Turner K., Hanson J., et al. Dose ratio between morphine and hydromorphone in patients with cancer pain A retrospective study. Pain. 72:1997;79-85
51. Miller M.G., McCarthy N., O'Boyle C.A., et al. Continuous subcutaneous infusion of morphine vs. hydromorphone A controlled trial. J Pain Symptom Manage. 18:1999;9-16
52. Dunbar P.J., Chapman C.R., Buckley F.P., et al. Clinical analgesic equivalence for morphine and hydromorphone with prolonged PCA. Pain. 68:1996;265-270
53. U.S. Department of Health and Human Services. Management of Cancer Pain. Clinical Practical Guidelines. 1994;U.S. Department of health and Human Services, Rockville, MD
54. Ripamonti C., Groff L., Brunelli C., et al. Switching from morphine to oral methadone in treating cancer pain What is the equianalgesic dose ratio? J Clin Oncol. 16:1998;3216-3221
55. Lawlor P.G., Turner K.S., Hanson J., et al. Dose ratio between morphine and methadone in patients with cancer pain A retrospective study. Cancer. 82:1998;1167-1173
56. Fitzgibbon D.R., Ready L.B. Intravenous high-dose methadone administered by patient controlled analgesia and continuous infusion for the treatment of cancer pain refractory to high-dose morphine. Pain. 73:1997;259-261
57. Moryl N., Santiago-Palma J., Kornick C., et al. Pitfalls of opioid rotation Substituting another opioid for methadone in patients with cancer pain. Pain. 96:2002;325-328
58. Vigano A., Fan D., Bruera E. Individualized use of methadone and opioid rotation in the comprehensive management of cancer pain associated with poor prognostic indicators. Pain. 67:1996;115-119
59. Gorman A.L., Elliott K.J., Inturrisi C.E. The d- and l-isomers of methadone bind to the non-competitive site on the N-methyl-D-aspartate (NMDA) receptor in rat forebrain and spinal cord. Neurosci Lett. 223:1997;5-8
60. Mao J., Price D.D., Mayer D.J. Mechanisms of hyperalgesia and morphine tolerance A current view of their possible interactions. Pain. 62:1995;259-274
61. Price D.D., Mayer D.J., Mao J., et al. NMDA-receptor antagonists and opioid receptor interactions as related to analgesia and tolerance. J Pain Symptom Manage. 19:2000;S7-S11
62. Woodhouse A., Hobbes A.F., Mather L.E., et al. A comparison of morphine, pethidine and fentanyl in the postsurgical patient-controlled analgesia environment. Pain. 64:1996;115-121
63. Hunt R., Fazekas B., Thorne D., et al. A comparison of subcutaneous morphine and fentanyl in hospice cancer patients. J Pain Symptom Manage. 18:1999;111-119
64. Paix A., Coleman A., Lees J., et al. Subcutaneous fentanyl and sufentanil infusion substitution for morphine intolerance in cancer pain management. Pain. 63:1995;263-269
65. Watanabe S., Pereira J., Hanson J., et al. Fentanyl by continuous subcutaneous infusion for the management of cancer pain A retrospective study. J Pain Symptom Manage. 16:1998;323-326
66. Fainsinger R.L., Bruera E. How should we use transdermal fentanyl (TF) for pain management in palliative care patients? J Palliat Care. 12:1996;48-53
67. Portenoy R.K., Southam M.A., Gupta S.K., et al. Transdermal fentanyl for cancer pain. Repeated dose pharmacokinetics. Anesthesiology. 78:1993;36-43
68. Grond S., Radbruch L., Lehmann K.A. Clinical pharmacokinetics of transdermal opioids Focus on transdermal fentanyl. Clin Pharmacokinet. 38:2000;59-89
69. Janssen Pharmaceutica Inc. Duragesic Product Information. 1990;. Piscataway, NJ
70. Donner B., Zenz M., Tryba M., et al. Direct conversion from oral morphine to transdermal fentanyl A multicenter study in patients with cancer pain. Pain. 64:1996;527-534
71. Streisand J.B., Varvel J.R., Stanski D.R., et al. Absorption and bioavailability of oral transmucosal fentanyl citrate. Anesthesiology. 75:1991;223-229
72. Lichtor J.L., Sevarino F.B., Joshi G.P., et al. The relative potency of oral transmucosal fentanyl citrate compared with intravenous morphine in the treatment of moderate to severe postoperative pain. Anesth Analg. 89:1999;732-738
73. Kaplan R., Parris W.C., Citron M.L., et al. Comparison of controlled-release and immediate-release oxycodone tablets in patients with cancer pain. J Clin Oncol. 16:1998;3230-3237
74. Beaver W.T., Wallenstein S.L., Rogers A., et al. Analgesic studies of codeine and oxycodone in patients with cancer. II. Comparisons of intramuscular oxycodone with intramuscular morphine and codeine. J Pharmacol Exp Ther. 207:1978;101-108
75. Kalso E., Vainio A. Morphine and oxycodone hydrochloride in the management of cancer pain. Clin Pharmacol Ther. 47:1990;639-646
76. Silvasti M., Rosenberg P., Seppala T., et al. Comparison of analgesic efficacy of oxycodone and morphine in postoperative intravenous patient-controlled analgesia. Acta Anaesthesiol Scand. 42:1998;576-580
77. Ginsberg B., Sinatra R.S., Adler L.J., et al. Conversion to oral controlled-release oxycodone from intravenous opioid analgesic in the postoperative setting. Pain Med. 4:2003;31-38
78. Curtis G.B., Johnson G.H., Clark P., et al. Relative potency of controlled-release oxycodone and controlled-release morphine in a postoperative pain model. Eur J Clin Pharmacol. 55:1999;425-429
79. Heiskanen T., Kalso E. Controlled-release oxycodone and morphine in cancer related pain. Pain. 73:1997;37-45
80. Bruera E., Belzile M., Pituskin E., et al. Randomized, double-blind, cross-over trial comparing safety and efficacy of oral controlled-release oxycodone with controlled-release morphine in patients with cancer pain. J Clin Oncol. 16:1998;3222-3229
81. Gagnon B., Bielech M., Watanabe S., et al. The use of intermittent subcutaneous injections of oxycodone for opioid rotation in patients with cancer pain. Support Care Cancer. 7:1999;265-270
82. Beaver W.T., Wallenstein S.L., Rogers A., et al. Analgesic studies of codeine and oxycodone in patients with cancer. I. Comparisons of oral with intramuscular codeine and of oral with intramuscular oxycodone. J Pharmacol Exp Ther. 207:1978;92-100